Biodexa Pharmaceuticals has developed platform technologies focused on improving the bio-delivery and bio-distribution of medications via sustained delivery, targeted delivery, or direct delivery.
Biodexa Pharmaceuticals flagship Q-Sphera™ platform uses 3D printing technology to encapsulate medicines into bioresorbable polymer microspheres. The mono dispersed microspheres can then be formulated into patient-friendly long-acting injectables.Discover More
Q-Sphera products directly benefit patients by maintaining consistent drug release within a tightly controlled therapeutic window. Q-Sphera products require smaller gauge needles, reducing injection site pain
Advanced 3D printing technology may be applied to a broad range of therapeutic and agents and is highly scalable, producing millions of homogenous microspheres per second with tuneable and precise characteristics
Q-Sphera products may be delivered via sub-cutaneous injection, reducing the need for office or outpatient visits and reducing cost to the healthcare system.
Biodexa Pharmaceuticals is building an innovative portfolio of first-to-sustained release treatments across multiple therapeutic areas with the most pressing unmet patient need.View Pipeline
At Biodexa Pharmaceuticals we recognise the power of partnership in developing and progressing the next generation of patient orientated medicines. We believe that our expertise and delivery technologies have the potential to transform medicines beyond our own pipeline, and that through partnership we can create value for all stakeholders and bring to market innovative and impactful medicines.Discover More
We are hiring. View our current vacancies×